New product Newswire: March 19, 2007

The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.

The drug is also approved for adults with chronic inflammatory demyelinating polyneuropathy.

The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.